Changmu Valley

Beijing Changmugu Medical Technology Co., Ltd (hereinafter referred to as "Changmugu"), founded in 2018, is a national high-tech enterprise with significant influence in the field of orthopaedic artificial intelligence and surgical robotics solutions, and is also a national specialized speciality and new "small giant" enterprise. "Small Giant" Enterprise.

Core Technology and Products

Longwood Valley Medical focuses on providing hospital orthopedics departments with full-process solutions such as artificial intelligence-assisted diagnosis, individualized surgical planning, surgical navigation robotics systems, and post-operative evaluation. Its core research team comes from Harvard University, Stanford University, Tsinghua University, Peking University and other world-class institutions, with top orthopedic medical background and solid technical capabilities.

• AI Joint System: The AI Joint System independently developed by Longwood Valley is the world's first AI joint replacement full-process solution, including the AIHIP AI Hip Replacement System and the AIKNEE AI Knee Replacement System. Through AI technology, 3D printing and surgical robotics, the system provides doctors with joint replacement solutions covering the entire process of pre-operative, intra-operative and post-operative surgery, which can significantly improve the precision, standardization and safety of orthopedic surgery.
• surgical robot: Longwood Valley is increasing its in-house R&D and clinical trials for the Super Navi handheld navigation robot and Super Robot orthopedic surgical tabletop robot segments to further expand its presence in the orthopedic surgical robotics space.

Market Reach and Collaboration

Changmugu Medical's products and services have covered 30 provincial-level administrative regions across the country and have been applied in thousands of tertiary hospitals, serving tens of thousands of orthopedic surgeries cumulatively. Meanwhile, Changmugu is also the first technology innovative enterprise in China that has established in-depth R&D cooperation and strategic partnership with top domestic and international hospitals and enterprises, such as Johnson & Johnson, Philips Healthcare, and the National Orthopaedic and Sports Rehabilitation Clinical Medical Research Center.

Financing and Honors

Changmugu Medical has completed seven rounds of financing (Series B+), with investors including IDG Capital, CDH Capital, CICC Capital, Softbank China, Lenovo Venture Capital, Lenovo Star, Yuan Sheng Venture Capital, Yuanhe Origin, Zhongguancun Development Group, Huajin Capital, Fenrirui Capital, and other domestic and international top venture capital organizations. The company has also won a number of honors, including national high-tech enterprise, "small giant" enterprise, Zhongguancun high-tech enterprise, Zhongguancun Eagle Talent Enterprise, Zhongguancun Golden Seed Enterprise, and Intellectual Property Demonstration Unit.

future outlook

In the future, Longwood Valley Medical will continue to plough into the orthopaedic field, optimize AI products and surgical navigation technology, and continue to introduce more intelligent solutions for surgical scenarios. The company plans to cover a series of diagnosis and treatment processes from disease screening, intelligent diagnosis, clinical decision-making, pre-operative planning, consumable selection, surgical simulation, surgical navigation and patient follow-up, and to promote the declaration and approval of clinical registration certificates. At the same time, Changmugu will continue to expand into more segments of orthopedics, such as spine, trauma, bone tumors, etc., and is committed to building a China-intelligent and world-leading orthopedic artificial intelligence and surgical navigation system to serve tens of millions of Chinese patients with orthopedic diseases.